

Patricia V Elizalde

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5231097/publications.pdf>

Version: 2024-02-01

46
papers

1,840
citations

279798

23
h-index

265206

42
g-index

48
all docs

48
docs citations

48
times ranked

2387
citing authors

#	ARTICLE	IF	CITATIONS
1	TNF α acting on TNFR1 promotes breast cancer growth via p42/P44 MAPK, JNK, Akt and NF- κ B-dependent pathways. <i>Experimental Cell Research</i> , 2008, 314, 509-529.	2.6	135
2	Progestins Induce Transcriptional Activation of Signal Transducer and Activator of Transcription 3 (Stat3) via a Jak- and Src-Dependent Mechanism in Breast Cancer Cells. <i>Molecular and Cellular Biology</i> , 2005, 25, 4826-4840.	2.3	113
3	Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells. <i>Oncogene</i> , 2001, 20, 34-47.	5.9	111
4	Progesterone Receptor Induces ErbB-2 Nuclear Translocation To Promote Breast Cancer Growth via a Novel Transcriptional Effect: ErbB-2 Function as a Coactivator of Stat3. <i>Molecular and Cellular Biology</i> , 2010, 30, 5456-5472.	2.3	98
5	Tumor Necrosis Factor α Blockade: An Opportunity to Tackle Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 584.	2.8	96
6	Downregulation of the tumor-suppressor miR-16 via progestin-mediated oncogenic signaling contributes to breast cancer development. <i>Breast Cancer Research</i> , 2012, 14, R77.	5.0	93
7	Progestin Effects on Breast Cancer Cell Proliferation, Proteases Activation, and in Vivo Development of Metastatic Phenotype All Depend on Progesterone Receptor Capacity to Activate Cytoplasmic Signaling Pathways. <i>Molecular Endocrinology</i> , 2007, 21, 1335-1358.	3.7	87
8	Heregulin Induces Transcriptional Activation of the Progesterone Receptor by a Mechanism That Requires Functional ErbB-2 and Mitogen-Activated Protein Kinase Activation in Breast Cancer Cells. <i>Molecular and Cellular Biology</i> , 2003, 23, 1095-1111.	2.3	83
9	Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2 α ER α GREB1 Transcriptional Axis. <i>Cancer Research</i> , 2018, 78, 671-684.	0.9	80
10	TNF α -Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 636-648.	7.0	74
11	Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity. <i>Oncogene</i> , 2004, 23, 5161-5174.	5.9	66
12	p42/p44 MAPK-mediated Stat3Ser727 phosphorylation is required for progestin-induced full activation of Stat3 and breast cancer growth. <i>Endocrine-Related Cancer</i> , 2013, 20, 197-212.	3.1	65
13	Activation of Stat3 by Heregulin/ErbB-2 through the Co-Option of Progesterone Receptor Signaling Drives Breast Cancer Growth. <i>Molecular and Cellular Biology</i> , 2009, 29, 1249-1265.	2.3	57
14	Interactions between progestins and heregulin (HRG) signaling pathways: HRG acts as mediator of progestins proliferative effects in mouse mammary adenocarcinomas. <i>Oncogene</i> , 1999, 18, 6370-6379.	5.9	50
15	Targeting Stat3 Induces Senescence in Tumor Cells and Elicits Prophylactic and Therapeutic Immune Responses against Breast Cancer Growth Mediated by NK Cells and CD4+ T Cells. <i>Journal of Immunology</i> , 2012, 189, 1162-1172.	0.8	46
16	ErbB-2 nuclear function in breast cancer growth, metastasis and resistance to therapy. <i>Endocrine-Related Cancer</i> , 2016, 23, T243-T257.	3.1	42
17	Clinical relevance of ErbB-2/HER2 nuclear expression in breast cancer. <i>BMC Cancer</i> , 2012, 12, 74.	2.6	38
18	Varying patterns of expression of insulin-like growth factors I and II and their receptors in murine mammary adenocarcinomas of different metastasizing ability. , 1996, 65, 812-820.		37

#	ARTICLE	IF	CITATIONS
19	Transactivation of ErbB-2 induced by tumor necrosis factor $\hat{I}\pm$ promotes NF- $\hat{I}\rho$ B activation and breast cancer cell proliferation. <i>Breast Cancer Research and Treatment</i> , 2010, 122, 111-124.	2.5	35
20	Small Interfering RNA Targeted to IGF-IR Delays Tumor Growth and Induces Proinflammatory Cytokines in a Mouse Breast Cancer Model. <i>PLoS ONE</i> , 2012, 7, e29213.	2.5	35
21	Heregulin inhibits proliferation via ERKs and phosphatidylinositol 3-kinase activation but regulates urokinase plasminogen activator independently of these pathways in metastatic mammary tumor cells. <i>International Journal of Cancer</i> , 2002, 100, 642-653.	5.1	34
22	Progesterone receptor activation downregulates GATA3 by transcriptional repression and increased protein turnover promoting breast tumor growth. <i>Breast Cancer Research</i> , 2014, 16, 491.	5.0	27
23	Immunization with Murine Breast Cancer Cells Treated with Antisense Oligodeoxynucleotides to Type I Insulin-Like Growth Factor Receptor Induced an Antitumoral Effect Mediated by a CD8+ Response Involving Fas/Fas Ligand Cytotoxic Pathway. <i>Journal of Immunology</i> , 2006, 176, 3426-3437.	0.8	25
24	Novel role of signal transducer and activator of transcription 3 as a progesterone receptor coactivator in breast cancer. <i>Steroids</i> , 2011, 76, 381-392.	1.8	23
25	Inhibition of MHC $\hat{A}\epsilon$ by <i>Brucella abortus</i> is an early event during infection and involves EGFR pathway. <i>Immunology and Cell Biology</i> , 2017, 95, 388-398.	2.3	23
26	Progesterin drives breast cancer growth by inducing p21CIP1 expression through the assembly of a transcriptional complex among Stat3, progesterone receptor and ErbB-2. <i>Steroids</i> , 2013, 78, 559-567.	1.8	22
27	Influence of conformationally restricted pyrimidines on the activity of 10 $\hat{A}\epsilon$ 23 DNAzymes. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 2581-2586.	3.0	20
28	Progesterone-induced stimulation of mammary tumorigenesis is due to the progesterone metabolite, 5 $\hat{I}\pm$ -dihydroprogesterone (5 $\hat{I}\pm$ P) and can be suppressed by the 5 $\hat{I}\pm$ -reductase inhibitor, finasteride. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2015, 149, 27-34.	2.5	20
29	Invasive micropapillary carcinoma of the breast overexpresses MUC4 and is associated with poor outcome to adjuvant trastuzumab in HER2-positive breast cancer. <i>BMC Cancer</i> , 2017, 17, 895.	2.6	20
30	Estrogen inhibition of MPA-Induced mouse mammary tumor transplants. <i>International Journal of Cancer</i> , 1991, 49, 900-905.	5.1	19
31	Involvement of insulin-like growth factors-I and -II and their receptors in medroxyprogesterone acetate-induced growth of mouse mammary adenocarcinomas. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1998, 67, 305-317.	2.5	18
32	Regulation of telomere homeostasis and genomic stability in cancer by $\langle i \rangle N \langle /i \rangle \langle \sup \rangle 6 \langle /sup \rangle$ -adenosine methylation (m $\langle \sup \rangle 6 \langle /sup \rangle$ A). <i>Science Advances</i> , 2021, 7, .	10.3	18
33	Blockade of Stat3 oncogene addiction induces cellular senescence and reveals a cell-nonautonomous activity suitable for cancer immunotherapy. <i>Oncolmmunology</i> , 2020, 9, 1715767.	4.6	14
34	Heregulin Co-opts PR Transcriptional Action Via Stat3 Role As a Coregulator to Drive Cancer Growth. <i>Molecular Endocrinology</i> , 2015, 29, 1468-1485.	3.7	12
35	Revisiting progesterone receptor (PR) actions in breast cancer: Insights into PR repressive functions. <i>Steroids</i> , 2018, 133, 75-81.	1.8	12
36	Mechanisms of Cell Cycle Arrest in Response to TGF- $\hat{I}2$ in Progesterin-Dependent and -Independent Growth of Mammary Tumors. <i>Experimental Cell Research</i> , 2001, 265, 152-166.	2.6	9

#	ARTICLE	IF	CITATIONS
37	Nuclear ErbB-2: a Novel Therapeutic Target in ErbB-2-Positive Breast Cancer?. Hormones and Cancer, 2019, 10, 64-70.	4.9	9

38